Amneal Pharmaceuticals, Inc. 8-K

What Happened
Amneal Pharmaceuticals, Inc. (AMRX) filed a Form 8-K on February 27, 2026 (Item 2.02) announcing its financial results for the fourth quarter and full year ended December 31, 2025. The company furnished a press release (Exhibit 99.1) with the results and scheduled a conference call and live webcast for 8:30 a.m. Eastern Time on February 27, 2026 to discuss the results.

Key Details

• The results cover the quarter and full year ended December 31, 2025; the full press release is attached as Exhibit 99.1 to the 8-K.
• Conference call/webcast: 8:30 a.m. ET on Feb 27, 2026; webcast via https://investors.amneal.com; U.S. dial-in (833) 470-1428, access code 937407. A replay will be posted after the call.
• Filing references Regulation FD disclosure (Item 7.01) for the call/webcast and includes the cover page in Inline XBRL (Exhibit 104).
• The Form 8-K was signed by Anastasios Konidaris, Executive VP and Chief Financial Officer, on behalf of the company.

Why It Matters
This 8-K signals that Amneal has published its latest quarterly and annual financial results and will provide management commentary in a live call—key opportunities for investors to hear revenue, earnings, cash flow, and any guidance or business updates. Retail investors should review the attached press release and listen to the webcast or replay for the specific financial figures and management discussion, since those details drive near-term market reactions and help assess operational performance.